An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202),Therapeutic Advances in Medical Oncology

当前位置： X-MOL 学术 › Ther. Adv. Med. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202)
Therapeutic Advances in Medical Oncology ( IF 4.3 ) Pub Date : 2020-03-19 , DOI: 10.1177/1758835920905424
Xiang Wang ₁ , Ruixing Zhang ₂ , Nan Du ₃ , Mudan Yang ₄ , Aimin Zang ₅ , Likun Liu ₆ , Junyan Yu ₇ , Jinghua Gao ₈ , Junping Zhang ₉ , Zhanzhao Fu ₁₀ , Yuchuan Ren ₁₁ , Liwen Ma ₁₂ , Jun Guo ₁₃ , Qingshan Li ₁₄ , Xiaomei Li ₁₅ , Zaiwen Fan ₁₆ , Xiang Song ₁₇ , Zheng Liu ₁₈ , Yan Zhang ₁₉ , Guozhong Li ₂₀ , Zhonghe Yu ₂₁ , Jianfeng Diao ₂₂ , Junmei Jia ₂₃ , Feng Liang ₂₄ , Huaqing Wang ₂₅ , Junzhong Sun ₃ , Yunge Gao ₂₆ , Ping Yang ₂₇ , Chunmei Bai ₂₈ , Xiubao Ren ₂₉ , Diansheng Zhong ₃₀

Affiliation

Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Department of Gastroenterology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Department of Medical Oncology, Fourth Medical Center of PLA General Hospital, Beijing, China.
Digestive Department of Oncology, Shanxi Tumor Hospital, Taiyuan, China.
Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Oncology Department, Shanxi Provincial Hospital of Traditional Chinese Medicine, Taiyuan, China.
Department of Oncology, Peace Hospital of Changzhi Medical College, Changzhi, China.
Department of Medical Oncology, Cangzhou Central Hospital, Cangzhou, China.
Department of Medical Oncology, Shanxi Academy of Medical Sciences, Shanxi Dayi Hospital, Taiyuan, China.
Department of Medical Oncology, First Hospital of Qinhuangdao, Qinhuangdao, China.
Oncology Department, Yangquan First People's Hospital, Yangquan, China.
Department of Tumor Chemotherapy and Radiology, Peking University Third Hospital, Beijing, China.
Department of Medical Oncology, Xingtai People's Hospital, Hebei Medical University Affiliated Hospital, Xingtai, China.
Department of Medical Oncology, Affiliated Hospital of Chengde Medical University, Chengde, China.
Department of Medical Oncology, Chinese PLA General Hospital, Medical School of Chinese PLA, Beijing, China.
Department of Medical Oncology, Air Force General Hospital, PLA, Beijing, China.
Department of Medical Oncology, Second Hospital of Shanxi Medical University, Taiyuan, China.
Department of Radiology, Handan Central Hospital, Handan, China.
Department of Medical Oncology, Shijiazhuang People's Hospital, Shijiazhuang, China.
Department of Medical Oncology, Peking University Binhai Hospital, Tianjin, China.
Department of Medical Oncology, Seventh Medical Center of PLA General Hospital, Beijing, China.
Department of Medical Oncology, Datong Second People's Hospital, Datong, China.
Department of Medical Oncology, First Hospital of Shanxi Medical University, Taiyuan, China.
Department of General Surgery, Fifth Medical Center of PLA General Hospital, Beijing, China.
Department of Medical Oncology, Tianjin People's Hospital, Tianjin, China.
Department of Hematology and Oncology, Strategic Support Force Characteristic Medical Center/Former The 306 Hospital of PLA, Beijing, China.
Department of Medical Oncology, Sixth Medical Center of PLA General Hospital, Beijing, China.
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No.1 Shuaifuyuan Wangfujing Dongcheng District, Beijing 100032, China.
Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.

Gastric cancer is one of the most frequent malignancies and currently the third leading cause of cancer-related mortality globally with approximately 723,000 deaths annually.^1,2 Despite the recent decline in the prevalence of gastric cancer in China, 498,000 gastric cancer deaths were estimated to have occurred in 2015 in the country,³ with a mortality of 15.6 per 100,000.⁴

更新日期：2020-04-21

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11